癌症免疫疗法，尤其是使用免疫检查点抑制剂，已成功改善恶性肿瘤的治疗局势。

Programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) blockade therapy is a new class of anticancer immunotherapy that utilizes the body’s immune system to resist cancer and causes cancer cell death by blocking the PD-1/PD-L1 signaling pathway.

下载此白皮书以了解有关PD-1/PD-L1的更多信息：

• 阻止治疗的阻力
• CTLA-4阻滞剂的组合疗法
• 与靶向药物EGFR联合疗法